NUVB (Nuvation Bio) Days Payable : 202.67 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio Days Payable?

Nuvation Bio's average Accounts Payable for the three months ended in Dec. 2024 was $9.36 Mil. Nuvation Bio's Cost of Goods Sold for the three months ended in Dec. 2024 was $4.22 Mil. Hence, Nuvation Bio's Days Payable for the three months ended in Dec. 2024 was 202.67.

The historical rank and industry rank for Nuvation Bio's Days Payable or its related term are showing as below:

NUVB' s Days Payable Range Over the Past 10 Years
Min: 220.63 Med: 220.63 Max: 294.81
Current: 294.81

During the past 5 years, Nuvation Bio's highest Days Payable was 294.81. The lowest was 220.63. And the median was 220.63.

NUVB's Days Payable is ranked better than
70.17% of 704 companies
in the Biotechnology industry
Industry Median: 123.485 vs NUVB: 294.81

Nuvation Bio's Days Payable increased from Dec. 2023 (0.00) to Dec. 2024 (202.67). It may suggest that Nuvation Bio delayed paying its suppliers.

Nuvation Bio Days Payable Historical Data

The historical data trend for Nuvation Bio's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Days Payable Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

220.63

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															-	-	259.02	529.76	202.67

Competitive Comparison of Nuvation Bio's Days Payable

For the Biotechnology subindustry, Nuvation Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvation Bio's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's Days Payable distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's Days Payable falls into.

Save Embed

;

Save Embed

;

Nuvation Bio Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Nuvation Bio's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (2.209	+	6.348)	/	2 )	/	7.078	*	365
=	4.2785					/	7.078	*	365
=	220.63

Nuvation Bio's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (12.38	+	6.348)	/	2 )	/	4.216	*	365 / 4
=	9.364					/	4.216	*	365 / 4
=	202.67

Nuvation Bio Days Payable Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Executives

Kim D Blickenstaff	director	C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
Oleg Nodelman	director	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc	director	1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Venture Opportunity Fund, Lp	director	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p.	director	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc	director	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund Qualified, L.p.	director	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Kathryn E Falberg	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dongfang Liu	officer: Chief Medical Officer	C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 401, NEW YORK NY 10036
Omega Fund V Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund Iv Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
David C. Hanley	officer: Chief Technical Operations	C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Stacy Markel	officer: SVP, Human Resources	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080